MARKET

XRTX

XRTX

Xortx Therapeutics Inc
NASDAQ
2.490
+0.205
+8.97%
After Hours: 2.460 -0.03 -1.20% 19:16 04/10 EDT
OPEN
2.250
PREV CLOSE
2.285
HIGH
2.600
LOW
2.250
VOLUME
44.11K
TURNOVER
--
52 WEEK HIGH
7.05
52 WEEK LOW
1.725
MARKET CAP
3.47M
P/E (TTM)
-0.8876
1D
5D
1M
3M
1Y
5Y
1D
XORTX publishes investor presentation outlining gout, kidney disease drug development strategy
Reuters · 1d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 2d ago
Weekly Report: what happened at XRTX last week (0330-0403)?
Weekly Report · 5d ago
XORTX Therapeutics Secures Exchange Approvals for 1-for-5 Share Consolidation Effective April 6
TipRanks · 04/01 19:59
Xortx Therapeutics to effect 5-for-1 share consolidation on April 6
TipRanks · 04/01 17:05
XORTX Therapeutics Announces 1-For-5 Share Consolidation, Effective April 6, 2026
Benzinga · 04/01 17:02
XORTX THERAPEUTICS INC - TO CONSOLIDATE SHARES 1-FOR-5 EFFECTIVE APRIL 6, 2026
Reuters · 04/01 17:00
XORTX to consolidate shares 1-for-5 effective April 6
Reuters · 04/01 17:00
More
About XRTX
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.

Webull offers XORTX Therapeutics Inc stock information, including NASDAQ: XRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XRTX stock methods without spending real money on the virtual paper trading platform.